Life-extending drug Enhertu will be available on the public health service in England, offering patients with advanced breast cancer an average survival benefit of around seven months. The decision brings the treatment into routine use on the NHS in England after it has been prescribed in Scotland for more than two years. The move is intended to widen access to a medicine that clinical studies have linked to a measurable extension in life expectancy for some patients.
The inclusion of the drug on the NHS list means clinicians working in cancer services will be able to prescribe it for patients who meet the service’s eligibility criteria. Implementation will follow the usual pathways for new treatments in the health service, with local cancer teams assessing suitability for individual patients. Health professionals and hospital pharmacies are expected to integrate the medicine into treatment protocols where it is judged clinically appropriate.
Scottish health services had placed the medicine into use earlier, providing a precedent for its clinical deployment within the United Kingdom’s devolved systems. The availability in NHS Scotland for more than two years has supplied additional experience for oncologists and care teams, which may inform practice in England. Observers say that differing timetables between nations can affect where and when patients gain access to new therapies.
The decision is likely to have implications for patients and services across England, including capacity planning and the management of treatment pathways in oncology units. Data collected during routine use will contribute to ongoing assessments of benefits, tolerability and longer-term outcomes. Providers and commissioning bodies will monitor use to ensure the treatment is delivered safely and to identify any operational challenges that arise during wider rollout.
Patients and families seeking further information are advised to speak with their clinical teams. Additional details about the health service and guidance on cancer care can be found through NHS England and local cancer support services, which can explain eligibility and next steps for those who may benefit from the new treatment option.
